Todd Strategy Group
lobbying firm
Todd Strategy Group's federal footprint as a lobbying firm — reported lobbying it billed or handled on behalf of the clients it represents (this is the firm's reported revenue for that work, not its own spending). Figures are as reported to the U.S. Senate (LDA).
Reported country: 🇺🇸 United States
Lobbying over time
| FY | Lobbying billed / handled (as firm) |
|---|---|
| 2022 | $8,700,000 |
| 2023 | $10,560,000 |
| 2024 | $13,280,000 |
| 2025 | $15,110,000 |
| 2026 | $730,000 |
Reported lobbying revenue for the clients Todd Strategy Group represents — not the firm's own spending.
Clients represented
- Medical Countermeasures Coalition $1,480,000 · 10 filings
- Alexion Pharmaceuticals, INC. $1,400,000 · 18 filings
- Amgen INC. $1,320,000 · 18 filings
- Novartis, INC. $1,290,000 · 19 filings
- Genentech, INC. $1,030,000 · 17 filings
- Pharmaceutical Research And Manufacturers Of America $1,020,000 · 17 filings
- Gilead Sciences, INC. $970,000 · 17 filings
- Siemens Healthineers $960,000 · 16 filings
- Alnylam Pharmaceuticals, INC. $940,000 · 17 filings
- Mckesson Corporation $900,000 · 18 filings
Clients Todd Strategy Group filed lobbying for, by reported amount billed/handled.
Issues
| Issue area | Worked |
|---|---|
| Health Issues | 575 |
| Medicare/Medicaid | 456 |
| Pharmacy | 125 |
| Budget/Appropriations | 68 |
| Copyright/Patent/Trademark | 46 |
| Taxation/Internal Revenue Code | 39 |
| Education | 28 |
| Tobacco | 17 |
| Banking | 16 |
| Telecommunications | 16 |
| Government Issues | 14 |
| Financial Institutions/Investments/Securities | 13 |
| Advertising | 12 |
| Communications/Broadcasting/Radio/TV | 12 |
| Economics/Economic Development | 10 |
| Labor Issues/Antitrust/Workplace | 10 |
| Science/Technology | 10 |
| Insurance | 8 |
| Medical/Disease Research/Clinical Labs | 8 |
| Trade (domestic/foreign) | 7 |
| Gaming/Gambling/Casino | 6 |
| Tariff (miscellaneous tariff bills) | 5 |
| Veterans | 5 |
Issue areas across Todd Strategy Group's filings, by activity count. Linked areas open the CivicGate issue page.
What they lobbied on
Reported activity from Senate LDA
-
FY2026 Medicare/Medicaid
General discussions around Medicare/Medicaid. Implementation of IRA.
-
FY2026 Health Issues
Policy to advance pharmaceutical research and development. 340B.
-
FY2026 Medicare/Medicaid
Implementation of Inflation Reduction Act of 2022.
-
FY2026 Copyright/Patent/Trademark
Intellectual property.
-
FY2026 Health Issues
General education about Freenome.
-
FY2026 Medicare/Medicaid
Medicare coverage and reimbursement for diagnostics.
-
FY2026 Health Issues
Drug Pricing Policy. Issues relating to mental health as a chronic condition. Agitation in Alzheimer's.
-
FY2026 Medicare/Medicaid
General education about Inflammatix. Medicare coverage and reimbursement for diagnostics.
Show 52 more activities
-
FY2026 Pharmacy
General education about Personalis. Lab test regulatory and reimbursement reform.
-
FY2026 Medicare/Medicaid
Medicare coverage and reimbursement for diagnostics.
-
FY2026 Health Issues
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
-
FY2026 Copyright/Patent/Trademark
IP and Bayh-Dole Act.
-
FY2026 Medicare/Medicaid
Medicare Part D.
-
FY2026 Pharmacy
Implementation of the Inflation Reduction Act. PSA screening bills. Health care transparency.
-
FY2026 Health Issues
NIH Strategic Plan. HIPAA Proposed Rule. Maternal health. Health care consolidation. ICD-11 implementation and other coding issues. Public Law 119-21: One Big Beautiful Bill Act. U.S. Preventive Services Task Force (USPSTF). AMA Physician Practice benchmark survey results. Vaccines and ACIP. Telehealth policy initiatives. H.R.7148: Consolidated Appropriations Act. Long-Term Care Rate Changes.
-
FY2026 Medicare/Medicaid
Alternative payment model bonuses and incentive payments and freezing the qualifying provider revenue thresholds. Interoperability and Prior Authorization Final Rule. Hospital Inpatient Prospective Payment Systems. CMMI Reforms. Medicare Access and CHIP Reauthorization Act (MACRA). Accountable Care Organizations (ACOs) and Alternative Payment Models (APMs) in Medicare. Indirect practice expense. Medicare physician payment issues. MIPS quality and cost measures.
-
FY2026 Pharmacy
Drug shortages.
-
FY2026 Health Issues
HIPAA Coordinated Care Rulemaking.
-
FY2026 Health Issues
Issues related to healthcare data privacy, cybersecurity, and artificial intelligence.
-
FY2026 Medicare/Medicaid
General Medicare/Medicaid Issues. Transparency Requirements. Emergency Preparedness.
-
FY2026 Medicare/Medicaid
General discussions around Medicare/Medicaid. Implementation of IRA.
-
FY2026 Copyright/Patent/Trademark
Copyright issues. Intellectual property protection.
-
FY2026 Health Issues
General issues related to rare disease and orphan drugs.
-
FY2026 Health Issues
Health insurance accessibility. Artificial Intelligence in health care.
-
FY2026 Medicare/Medicaid
Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access. CMS National Coverage Determination on Alzheimer's disease. Implementation of the Inflation Reduction Act.
-
FY2026 Pharmacy
Drug pricing, coverage, value, access and quality. Prescription drug approval. Drug importation. 340 B. Intellectual property. Pharmaceutical supply chain issues and shortages. Transparency. Issues related to intellectual property protection and market access within current trade negotiations.
-
FY2025 Health Issues
Organ procurement regulations. Increasing access to organ transplant.
-
FY2025 Taxation/Internal Revenue Code
Tax policy related to qualified business investment tax credit.
-
FY2025 Health Issues
Prescription Drug Pricing. Implementation of Inflation Reduction Act of 2022.
-
FY2025 Medicare/Medicaid
General Medicare/Medicaid Issues. Safe STEP Act. 340B Issues.
-
FY2025 Education
S.2296 - National Defense Authorization Act for Fiscal Year 2026.
-
FY2025 Health Issues
Policy to advance pharmaceutical research and development. 340B.
-
FY2025 Medicare/Medicaid
Implementation of Inflation Reduction Act of 2022.
-
FY2025 Copyright/Patent/Trademark
Intellectual property.
-
FY2025 Medicare/Medicaid
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
-
FY2025 Telecommunications
Spectrum. General telecommunications issues.
-
FY2025 Medicare/Medicaid
Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.
-
FY2025 Health Issues
Prescription Drug Pricing Policy. Supply Chain Issues.
-
FY2025 Taxation/Internal Revenue Code
Prescription drug pricing policy.
-
FY2025 Medicare/Medicaid
Medicare and Medicaid issues. 340B Issues. Drug pricing. Implementation of IRA. Supply chain issues.
-
FY2025 Health Issues
Medicare and Medicaid issues. 340B Issues. Drug pricing. Implementation of IRA. Supply chain issues.
-
FY2025 Education
General education issues. H.R.1383 - Secure Rural Schools Reauthorization Act of 2025.
-
FY2025 Health Issues
Rare Disease Issues.
-
FY2025 Medicare/Medicaid
General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022.
-
FY2025 Pharmacy
Prescription drug pricing. Prostate cancer screening. Women's health.
-
FY2025 Health Issues
Prescription drug pricing. Prostate cancer screening. Women's health.
-
FY2025 Medicare/Medicaid
General Medicare / Medicaid Issues. Medicare Rulemaking. Medicare reimbursement for radiation oncology. Telehealth.
-
FY2025 Pharmacy
Drug product quality assurance.
-
FY2025 Health Issues
Biosecurity Issues.
-
FY2025 Economics/Economic Development
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
-
FY2025 Taxation/Internal Revenue Code
General education around APVA and its mission to promote American competitiveness, including issues related to tax policy and economic opportunity and growth.
-
FY2025 Pharmacy
PBM Policy Reform. Prior authorization. Utilization management.
-
FY2025 Tobacco
Discussions related to implementation of P.L. 111-31 Family Smoking Prevention and Tobacco Control Act. Discussions related to tobacco harm reduction. Discussions related to enforcement of illicit tobacco products, including importation of counterfeit products. Discussions related to user fees for tobacco and electronic nicotine delivery system products. Discussions related to efforts to prevent youth access to tobacco products.
-
FY2025 Budget/Appropriations
Discussions concerning the FY 2024 appropriations bills; provisions related to FDA regulation of tobacco.
-
FY2025 Government Issues
Discussions concerning federal funding related to the Centers for Disease Control and Prevention.
-
FY2025 Medicare/Medicaid
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
-
FY2025 Health Issues
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.
-
FY2025 Medicare/Medicaid
340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.
-
FY2025 Health Issues
General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy.
-
FY2025 Health Issues
Biosecurity Issues.
The specific issues and bills Todd Strategy Group reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.